Monopar Therapeutics
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL, 60091
Mailing Address 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL, 60091
Phone 8473880349
Fiscal Year End 1231
EIN 320463781
Financial Overview
FY2024 FY
-
Revenue
-$8.40M
Net Income
$7.35M
Total Assets
$5.25M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 6, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | December 29, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 17, 2025 | View on SEC |
| 4 Insider stock transaction report | December 17, 2025 | View on SEC |
Insider Trading
SELL 2 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.